Clinical Trials on Myeloma-Associated Amyloidosis

Total 9474 results

Washington University School of Medicine
Karyopharm Therapeutics Inc

Recruiting

Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Multiple Myeloma | Myeloma-Associated Amyloidosis

United States
Pfizer

Completed

The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis

Transthyretin-associated Amyloidosis With Polyneuropathy

United States, France, Germany, Italy
Selayang Hospital

Completed

A Randomised, Open-Label, Cross Over Group, Single-Centre Controlled Study To Evaluate The Clinical Performance Of Medium Cut-Off Membrane Dialyser Compared With High Flux Dialyser Among Patients With Chronic Haemodialysis (HD-1)

Quality of Life | Dialysis Amyloidosis | Hemodialysis-Associated Amyloidosis

Malaysia
Margarida Magalhaes-Silverman
National Cancer Institute (NCI)

Completed

Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Primary Systemic Amyloidosis | Light Chain Deposition Disease | Extramedullary Plasmacytoma | Isolated Plasmacytoma of Bone

United States
Sanofi

Recruiting

A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

Relapsed/Refractory Multiple Myeloma | Amyloid Light-chain Amyloidosis

Italy, Australia, Hungary, United Kingdom, Czechia, Belgium, Spain
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Amyloidosis | Plasma Cell Myeloma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

Multiple Myeloma | Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
Celgene

Terminated

Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Plasma Cell Myeloma | Secondary Amyloidosis

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
Alnylam Pharmaceuticals

Completed

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Amyloid Neuropathies | Amyloid Neuropathies, Familial | Amyloidosis, Hereditary | Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) | Amyloidosis, Hereditary, Transthyretin-Related | Familial Transthyretin Cardiac Amyloidosis

United States, France, Italy, Spain, Canada, Germany, Belgium, Sweden, United Kingdom
Takeda

Completed

A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice (DOrianT)

Multiple Myeloma | Immunoglobulin Light-chain Amyloidosis

Spain
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

Primary Systemic Amyloidosis | Light Chain Deposition Disease

United States, Canada
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Completed

4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States, Italy
Tufts Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
Alnylam Pharmaceuticals

Completed

DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis

Familial Amyloidotic Cardiomyopathy (FAC)

United States, France, Spain, United Kingdom, Belgium, Brazil
City of Hope Medical Center

Completed

Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma

Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Secondary Amyloidosis

United States
Tufts Medical Center
National Institute on Aging (NIA)

Completed

Screening to Improve Survival in AL Amyloidosis

Monoclonal Gammopathy of Undetermined Significance | Smoldering Multiple Myeloma

United States
Alnylam Pharmaceuticals

Completed

The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant

ATTR Amyloidosis | Transthyretin (TTR)-Mediated Amyloidosis | Familial Amyloidotic Polyneuropathy (FAP) | Familial Amyloid Neuropathies

France, Germany, Portugal, United Kingdom, Sweden, Spain
IRCCS Policlinico S. Matteo

Recruiting

Promoting Diagnosis and Management of AL in Italy (ProDigALIty) (ProDigALIty)

AL Amyloidosis | Monoclonal Gammopathy of Undetermined Significance | Smoldering Multiple Myeloma

Italy
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

Primary Systemic Amyloidosis | Light Chain Deposition Disease

United States
Boston Medical Center

Completed

Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis (MRD)

Multiple Myeloma

United States
Southwest Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B

Completed

S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC

Active, not recruiting

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

Multiple Myeloma | AL Amyloidosis

United States
Vaishali Sanchorawala
Celgene Corporation

Completed

CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma

United States
Boston Medical Center

Completed

Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma

United States
M.D. Anderson Cancer Center

Completed

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

Multiple Myeloma | Primary Amyloidosis

United States
Nanjing University School of Medicine

Enrolling by invitation

Autologous Stem Cell Transplantation for Patients With AL Amyloidosis

AL Amyloidosis | Plasma Cell Dyscrasia

China
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Relapsed or Refractory Multiple Myeloma | Previously Treated Amyloid Light-chain (AL) Amyloidosis

Belgium, United States, United Kingdom, Spain, France, Netherlands
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Terminated

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Multiple Myeloma and Plasma Cell Neoplasm | Drug/Agent Toxicity by Tissue/Organ

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis

Light-Chain Amyloidosis

United States, Canada, France, Germany, Italy
Boston University
Corino Therapeutics, Inc.

Completed

Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)

Transthyretin Amyloidosis | Amyloidosis, Leptomeningeal, Transthyretin-Related

United States
Chulalongkorn University

Unknown

Efficacy of Methylene Blue Mediated Photodynamic Therapy for Primary Localized Cutaneous Amyloidosis Treatment in Asians

Lichen Amyloidosis

Thailand
Criterium, Inc.
Amgen

Completed

A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis

Amyloidosis | Systemic Light Chain Amyloidosis

United States
Steen Hvitfeldt Poulsen

Recruiting

Prevalence of wtATTR-CM After Carpal Tunnel Release Surgery (CACTuS2)

Transthyretin Amyloidosis | Transthyretin Cardiac Amyloidosis | Wild-Type Transthyretin-Related (ATTR)Amyloidosis

Denmark
IRCCS Policlinico S. Matteo

Recruiting

The Italian Transthyretin Amyloidosis Web-Network (ITA-WebNet)

ATTR Amyloidosis

Italy
University Hospital Center of Martinique

Terminated

Mitochondrial Function in Transthyretin Amyloidosis (MIT-Amylose)

Cardiac Amyloidosis

Martinique
Kaneka Medical America LLC

Recruiting

Post Approval Study of Lixelle for the Treament of Dialysis-Related Amyloidosis

Dialysis Amyloidosis

United States
Peking Union Medical College Hospital
Xian-Janssen Pharmaceutical Ltd.

Active, not recruiting

Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis

Amyloidosis; Systemic

China
Peking Union Medical College Hospital

Active, not recruiting

Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)

Light Chain (AL) Amyloidosis | Venetoclax | CCND1 Translocation

China
Tufts Medical Center
Sanofi

Withdrawn

Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis

Amyloidosis | Light Chain (AL) Amyloidosis
Austin Neuromuscular Center
Alnylam Pharmaceuticals

Recruiting

Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy

Polyneuropathies | Transthyretin Amyloidosis | Wild-Type Transthyretin-Related (ATTR)Amyloidosis | Wild-Type Transthyretin Cardiac Amyloidosis | Wild Type ATTR Amyloidosis

United States
Midwest Heart & Vascular Specialists

Recruiting

Amyloidosis Incidence in High-Risk Cardiac Device Patients

AL Amyloidosis | Amyloid | Cardiac Amyloidosis | Amyloidosis Cardiac | Systemic Amyloidosis | ATTR Amyloidosis Wild Type | Infiltrative Cardiomyopathy, Amyloid

United States
University of Tennessee Graduate School of Medicine
Attralus, Inc.

Recruiting

A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis

Systemic Amyloidosis

United States
Samsung Medical Center

Recruiting

Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis

Cardiac Amyloidosis

Korea, Republic of
Mayo Clinic

Enrolling by invitation

Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis

Cardiac Amyloidosis

United States

Clinical Trials on Myeloma-Associated Amyloidosis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations